Schott Pharma has opened a glass manufacturing facility in Jagodina, Serbia to strengthen its competitiveness in Europe.

The company's double-digit million euro investment will create approximately 180 jobs by the end of 2025.

The facility took less than 1.5 years to construct, having broken ground in December 2023.

The site will manufacture glass ampoules for the storage of injectable medications such as analgesics, anti-inflammatories and anaesthetics.

With this step, Schott Pharma aims to increase its competitiveness in the field of drug containment solutions.

Andreas Reisse, CEO of Schott Pharma, said: “At a time when global tariffs and duties are rising and other European-based glass ampoule manufacturers are closing their doors, we can offer our regional customers a clear long-term perspective on how to secure their local supply chain.”

With over 40% of the world's commercial injectable drugs stored in glass ampoules, Schott Pharma’s ampoule production in Serbia will continue to help the pharmaceutical industry deliver medicines to patients safely.

The facility (see left) is equipped with modern manufacturing technology and inspection systems to produce products to the highest quality standards.

Schott Pharma's Type I borosilicate glass ampoule portfolio ranges from clear or amber glass types to different shapes (B, C, D) and breakage systems (one point cut, scoring, colour break) and is available with or without printing.

It includes more than a thousand different articles, all manufactured in accordance with current Good Manufacturing Practices (cGMP).

Schott Pharma ampoules emphasise uniform dimensions and high cosmetic quality to ensure seamless compatibility with automated filling lines, to minimise downtime and reduce waste.

As a result, they meet evolving industry standards and requirements and help pharmaceutical companies optimise efficiency and achieve product integrity, contributing to long-term cost savings.